Search | Clinical Trials Finder

Conditions: Erectile Dysfunction
Interventions: TA-1790, Sildenafil citrate, Placebo, Nitrostat; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 30 Years to 60 Years · Male only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 19
States / cities: El Cajon, California • Murrieta, California • Rialto, California + 14 more

Conditions: COVID-19
Interventions: ALG-097558, Dabigatran, Itraconazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Metastatic Colorectal Carcinoma, Neuropathy
Interventions: BXQ-350, Placebo; Drug · Other
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 12
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 9 more

Conditions: Vitamin D Deficiency
Interventions: 1,000 IU vitamin D2, placebo capsule, mushrooms, UVB-treated mushrooms, 400 IU vitamin D2, UVB-treated mushrooms, 1,000 IU vitamin D2; Dietary Supplement · Other
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 20 Years to 59 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Davis, California

Conditions: Asthma
Interventions: CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP); Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 134
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more

Conditions: HIV Prevention
Interventions: PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hidradenitis Suppurativa
Interventions: Lutikizumab, Placebo; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more

Conditions: Hepatitis, Hepatitis C
Interventions: Filibuvir, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 30
States / cities: Anaheim, California • Coronado, California • La Jolla, California + 22 more

Conditions: Hepatitis C Virus Infection
Interventions: Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more

Conditions: Healthy Volunteers
Interventions: Lorazepam 1 mg IM, Inhaled loxapine 10 mg, Inhaled Placebo, Placebo IM; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 50 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Diabetes Mellitus, Type 1
Interventions: Antioxidant supplement, Diabetes treatment, Regular Insulin; Dietary Supplement · Other · Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 21 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, Bupropion, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678 500 mg, JNJ-53718678 80 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 13
States / cities: Cerritos, California • Chula Vista, California • Garden Grove, California + 10 more

Conditions: Solid Tumors
Interventions: E7080, Comparator Drug, Comparator Drug: Sorafenib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Torrance, California • Chicago, Illinois • Detroit, Michigan

Conditions: General Anesthesia
Interventions: HSK3486, Propofol, Placebo; Drug
Lead sponsor: Haisco-USA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hyperphosphatemia
Interventions: DS-2330b PIB, Placebo, Sevelamer, DS-2330b Tablet; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Alzheimer's Disease
Interventions: Bryostatin for Injection, Placebo; Drug
Lead sponsor: Blanchette Rockefeller Neurosciences Insitute; Other
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Healthy Non-dependent, Recreational Sedative Users, Abuse Potential
Interventions: Suvorexant, Zolpidem, Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hepatitis C Infection, Thrombocytopenia
Interventions: romiplostim, ribavirin, placebo, PEG-interferon alfa-2a, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hypercholesterolemia
Interventions: Inclisiran, Ezetimibe, Matching Placebo for Inclisiran, Matching Placebo for Ezetimibe; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more

Conditions: Systemic Lupus Erythematosus
Interventions: Belimumab 10 mg/kg, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more

Conditions: Smallpox
Interventions: MVA Smallpox Vaccine, Placebo, Live vaccinia virus vaccine; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Effect of Consumption of Post-harvest UV-B Treated Mushrooms on Vitamin D Status of Healthy Adults

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

ADASUVE-Lorazepam Drug-Drug Interaction

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

ACAM 3000 MVA at Harvard Medical School